A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy ofSRP-9001 in Subjects With Duchenne Muscular Dystrophy

Project: Research project

Project Details

Description

A Phase 3 Multinational, Randomized, Double- Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy
StatusFinished
Effective start/end date6/1/2211/1/22

Funding

  • SAREPTA THERAPEUTICS, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.